Trial Profile
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Olaratumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 14 Dec 2021 Number of treatment arms have been changed from 4 to 5 as "cohort expansion" arm was added in phase 1b with new participants enrolled to confirm the safety of the olaratumab 20 mg/kg dose prior to opening the Phase 2. Timeframe for the primary end-point "overall survival" is increased from 9 months to 29 months.
- 14 Dec 2021 Status changed from active, no longer recruiting to completed.
- 19 Aug 2021 This trial has been completed in Germany, according to European Clinical Trials Database.